【摘要】 目的观察吉西他滨(商品名:健择)与奥沙利铂(GO方案)联合治疗晚期非小细胞肺癌(NSCLC)临床疗效及无进展生存期。方法采用GO方案治疗NSCLC 38例,男25例,女13例,吉西他滨1000mg/m2,静脉滴注,第1、8天,奥沙利铂130mg/m2,静脉滴注,第1天。21d为1周期,治疗至少2个周期。结果完全缓解(CR)3例;部分缓解(PR)12例,稳定(SD)16例,进展(PD)3例,总有效率47.22%。平均无疾病进展生存期(PFS)为6.38个月,主要不良反应为骨髓抑制。结论吉西他滨与奥沙利铂联合治疗晚期非小细胞肺癌(NSCLC)疗效肯定,不良反应轻,可提高局部控制率和1年生存率。更多还原

【Abstract】 Objective Observe the efficacy and progress-free survival of the combination of Oxaliplatin combined with Gemcitabine in the treatment of advanced non-small cell lung cancer(NSCLC).Methods There were 38 cases of advanced NSCLC patients who were treated with Oxaliplatin and Gemcitabine including 25 cases of male and 13 cases of female.Gemcitabine at the dose of 10000mg/m2 was administered on day 1 and 8 by intravenous infusion,followed by Oxaliplatin at 130mg/m2 given on day 1.The chemotherapy cycles were repeated every 21 days,and the patients received at least 2 cycles.Results 3 of them achieved complete remission(CR),12 got partial remission(PR),16 patients attain stable disease(SD),while 3 of them entered into progressive disease(PD).The overall response rate was 47.22%.The main toxicities was myelosuppression.Conclusion The treatment of Oxaliplatin combined with Gemcitabine is effective,meanwhile has low toxicity and less side reactions,and it could improve the local control rate and one-year survival rate.更多还原